SCHEMBL14656269

SCHEMBL14656269

CCOC(=O)Cc1cnc(Oc2ccc(F)c(F)c2)c(F)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 4/20 0.49
F10 P00742 1/20 0.43
PDE4A P27815 1/20 0.39
PDE4B Q07343 1/20 0.39
PDE4D Q08499 1/20 0.39
CARM1 Q86X55 1/20 0.39
PRMT6 Q96LA8 1/20 0.39
MAOA P21397 1/20 0.39
LMNA P02545 1/20 0.39
TBXAS1 P24557 1/20 0.38
CHRNA7 P36544 2/20 0.38
KMT2A Q03164 2/20 0.38
EGLN1 Q9GZT9 1/20 0.37
VNN1 O95497 1/20 0.37
ALDH1A1 P00352 1/20 0.37
NPC1 O15118 1/20 0.36
PKM P14618 1/20 0.36
NFKB1 P19838 1/20 0.36
RAB9A P51151 1/20 0.36
NFKB2 Q00653 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14656384 0.83 MAOB (0.49) MAOBF10PDE4BMAOATBXAS1
SCHEMBL14656159 0.83 P2RY12 (0.44) MAOBF10PDE4BCARM1PRMT6
SCHEMBL27751427 0.81 MAOB (0.47) MAOBF10ALDH1A1NPC1PKM
SCHEMBL14667763 0.81 TRPA1 (0.42) MAOBPDE4APDE4BPDE4DCARM1
SCHEMBL14667766 0.78 SMN1; SMN2 (0.40) MAOBPDE4APDE4BPDE4DCARM1
SCHEMBL14656579 0.78 TRPA1 (0.42) MAOBPDE4APDE4BPDE4DCARM1
SCHEMBL29255432 0.78 LTA4H (0.43) MAOBLMNAL3MBTL1
SCHEMBL165276 0.77 ALDH1A1 (0.50) MAOBMAOALMNAALDH1A1NPC1
SCHEMBL16046729 0.76 MAOB (0.62) MAOBMAOAALDH1A1NPC1PKM
SCHEMBL14656218 0.76 TRPA1 (0.40) MAOBPDE4APDE4BPDE4DCARM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9273054-B2 Substituted pyrimido[1,6-a]pyrimidines as Lp-PLA2 inhibitors GLAXO GROUP LIMITED (GB) 2016-03-01 US disclosed
US-9273054-B2 Substituted pyrimido[1,6-a]pyrimidines as Lp-PLA2 inhibitors GLAXO GROUP LIMITED (GB) 2016-03-01 US disclosed
US-20140179716-A1 BICYCLIC PYRIMIDONE COMPOUNDS GLAXO GROUP LIMITED (GB) 2014-06-26 US disclosed
US-20140179716-A1 BICYCLIC PYRIMIDONE COMPOUNDS GLAXO GROUP LIMITED (GB) 2014-06-26 US disclosed
EP-2736908-A1 BICYCLIC PYRIMIDONE COMPOUNDS Glaxo Group Limited (GB) 2014-06-04 EP disclosed
US-20130030012-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2013-01-31 US disclosed
US-20130030012-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2013-01-31 US disclosed
WO-2013014185-A1 BICYCLIC PYRIMIDONE COMPOUNDS GLAXO GROUP LIMITED (GB) 2013-01-31 WO disclosed
WO-2013014185-A1 BICYCLIC PYRIMIDONE COMPOUNDS GLAXO GROUP LIMITED (GB) 2013-01-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140179716-A1 BICYCLIC PYRIMIDONE COMPOUNDS PLA2G7, PLA2G4A, PLA2G1B MAOB 356/4885F10 3066/4885PDE4A 260/4885
US-20130030012-A1 COMPOUNDS LPCAT1, PLA2G7, PLAAT2 MAOB 474/4885F10 1207/4885PDE4A 278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.